ArticleBMJ open2026
Methadone administration and QT interval prolongation: protocol for a systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMethadone is a long-acting opioid used to treat opioid use disorder, cancer pain and provide perioperative analgesia. Methadone administration has been associated with QTc interval prolongation and consequently an increased risk of ventricular arrhythmias. This mechanism appears to be mediated by HERG channel inhibition, drug-drug interactions and genetic susceptibility. This protocol describes the methodology for a systematic review and meta-analysis aiming to evaluate the association between methadone administration and QTc prolongation and estimate the odds of major cardiac events. Our leading hypothesis is that methadone exerts a dose-dependent and time-dependent effect on QT prolongation. METHODS AND ANALYSIS: We will conduct a systematic literature search of randomised controlled trials, prospective and retrospective cohort studies and case-control studies involving adult or paediatric patients receiving oral or intravenous methadone for opioid use disorder, cancer-related pain and surgical pain. Searches will be performed in Ovid MEDLINE, Ovid Embase, Cochrane CENTRAL, Web of Science and ClinicalTrials.gov. The primary outcome will be QTc interval length (in milliseconds). Secondary outcomes will include odds of clinically significant QTc prolongation and major adverse cardiac events. Comparator groups will include baseline pre-methadone QTc measurements and an external control group not exposed to methadone. Random-effects meta-analyses will be conducted, reporting mean differences with 95% CIs. Prespecified subgroup analyses based on methadone dose and duration of exposure will be performed when feasible. Risk of bias will be assessed using the Cochrane Risk of Bias 2 tool for randomised studies and Risk Of Bias In Non-Randomised Studies-of Interventions for non-randomised studies. The certainty of evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. ETHICS AND DISSEMINATION: Ethical approval is not required. We will include data obtained exclusively from previously published peer-reviewed studies available in reputable databases. The results of this study are intended for dissemination via publication in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD420251143441.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.